ArticleImmunity, inflammation and disease2026
Role of LIGHT in the Inflammatory Mechanisms of Psoriasis via Upregulation of Proliferation and Cytokine Production of Keratinocytes.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of LIGHT in the Inflammatory Mechanisms of Psoriasis via Upregulation of Proliferation and Cytokine Production of Keratinocytes.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe pathogenesis of psoriasis is associated with abnormalities in immune pathways. HVEM is known as a receptor of LIGHT (homologous to lymphotoxins, inducible, and competes with HSV glycoprotein D), which is a newly identified member of the TNF superfamily. The expression of HVEM and LTBR (another LIGHT receptor) has been found to be increased in the skin of psoriasis patients. This indicates the potential role of LIGHT and its receptors in the pathogenesis of psoriasis. Therefore, the objective of this study was to examine the effect of LIGHT on keratinocyte proliferation and its therapeutic potential in the treatment of psoriasis.
methodsWe used immunohistochemistry to examine their expression in psoriasis-affected and normal tissue samples. We treated cells of the keratinocyte cell line HaCat with LIGHT protein, anti-HVEM and anti-LTβR antibodies, HVEM interference and LTβR interference RNA vectors, and NF-κB and JNK/AP-1 inhibitors at various concentrations and for various times, separately or simultaneously. The expression of NF-κB was examined by immunofluorescence staining, and the expression of inflammatory proteins was measured with ELISA. Further, the viability of HaCat cells was examined with a CCK-8 kit. In addition, flow cytometry was used to detect the expression of HVEM and LTBR on HaCat cells.
resultsWe found that LIGHT treatment of HaCat cells promoted the nuclear translocation of NF-κB. Further, the expression of p-c-Jun, IL-6, IL-8, PGI2, and PTGS2 was increased in response to LIGHT treatment, but the expression of these factors was decreased when the LIGHT receptors were blocked or NF-κB and JNK/AP-1 expression was inhibited. We also found that the viability of HaCat cells was consistent with the expression of pro-inflammatory factors.
conclusionsThe present findings indicate that the JNK/AP-1-HVEM-LIGHT pathway played a role in the viability of human keratinocytes and the expression of IL-6, IL-8, PGI2, and PTGS2. Thus, the JNK/AP-1-HVEM-LIGHT pathway might be a potential target for the treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.